The α7 nicotinic acetylcholine receptor ligands methyllycaconitine, NS6740 and GTS-21 reduce lipopolysaccharide-induced TNF-α release from microglia

Journal of Neuroimmunology

Volumn 251, Issue 1-2, 2012, Pages 65-72

  Thomsen, Morten S ^a   Mikkelsen, Jens D ^a  

^a Rigshospitalet   (Denmark)

Author keywords

A 1 42; GTS 21; Inflammation; Mitogen activated protein kinase; Neuroinflammation; Nicotinic acetylcholine receptor

Indexed keywords

1,4 DIAZABICYCLO[3.2.2]NONAN 4 YL [5 [3 (TRIFLUOROMETHYL)PHENYL]FURAN 2 YL]METHANONE; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; ANTIINFLAMMATORY AGENT; BUNGAROTOXIN RECEPTOR; METHYLLYCACONITINE; MITOGEN ACTIVATED PROTEIN KINASE; NS 6740; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; FEMALE; MICROGLIA; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

ACONITINE; ANIMALS; ANTI-INFLAMMATORY AGENTS; AZABICYCLO COMPOUNDS; BENZYLIDENE COMPOUNDS; FURANS; LIPOPOLYSACCHARIDES; MALE; MAP KINASE SIGNALING SYSTEM; MICROGLIA; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865645594     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.07.006     Document Type: Article

References (55)

1. Alkondon M., Pereira E.F., Wonnacott S., Albuquerque E.X. Blockade of nicotinic currents in hippocampal neurons defines methyllycaconitine as a potent and specific receptor antagonist. Mol. Pharmacol. 1992, 41:802-808.
2. Alkondon M., Pereira E.F., Cortes W.S., Maelicke A., Albuquerque E.X. Choline is a selective agonist of alpha7 nicotinic acetylcholine receptors in the rat brain neurons. Eur. J. Neurosci. 1997, 9:2734-2742.
3. Bencherif M., Lippiello P.M., Lucas R., Marrero M.B. Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases. Cell. Mol. Life Sci. 2011, 68:931-949.
4. Bertrand D., Gopalakrishnan M. Allosteric modulation of nicotinic acetylcholine receptors. Biochem. Pharmacol. 2007, 74:1155-1163.
5. Bertrand D., Devillers-Thiéry A., Revah F., Galzi J.L., Hussy N., Mulle C., Bertrand S., Ballivet M., Changeux J.P. Unconventional pharmacology of a neuronal nicotinic receptor mutated in the channel domain. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:1261-1265.
6. Bitner R.S., et al. Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J. Neurosci. 2007, 27:10578-10587.
7. Biton B., et al. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile. Neuropsychopharmacology 2007, 32:1-16.
8. Briggs C.A., et al. Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol. Biochem. Behav. 1997, 57:231-241.
9. Briggs C.A., Grønlien J.H., Curzon P., Timmermann D.B., Ween H., Thorin-Hagene K., Kerr P., Anderson D.J., Malysz J., Dyhring T., Olsen G.M., Peters D., Bunnelle W.H., Gopalakrishnan M. Role of channel activation in cognitive enhancement mediated by alpha7 nicotinic acetylcholine receptors. Br. J. Pharmacol. 2009, 158:1486-1494.
10. Buckingham S.D., Jones A.K., Brown L.A., Sattelle D.B. Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection. Pharmacol. Rev. 2009, 61:39-61.
11. Chromy B.A., Nowak R.J., Lambert M.P., Viola K.L., Chang L., Velasco P.T., Jones B.W., Fernandez S.J., Lacor P.N., Horowitz P., Finch C.E., Krafft G.A., Klein W.L. Self-assembly of A into globular neurotoxins † 2003, Direct:12749-12760.
12. Cui W.-Y., Li M.D. Nicotinic modulation of innate immune pathways via α7 nicotinic acetylcholine receptor. J. Neuroimmune Pharmacol. 2010, 5:479-488.
13. Dani J.A., Radcliffe K.A., Pidoplichko V.I. Variations in desensitization of nicotinic acetylcholine receptors from hippocampus and midbrain dopamine areas. Eur. J. Pharmacol. 2000, 393:31-38.
14. De Simone R., Ajmone-Cat M.A., Carnevale D., Minghetti L. Activation of alpha7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. J. Neuroinflammation 2005, 2:4.
15. Dinklo T., Shaban H., Thuring J.W., Lavreysen H., Stevens K.E., Zheng L., Mackie C., Grantham C., Vandenberk I., Meulders G., Peeters L., Verachtert H., De Prins E., Lesage A.S.J. Characterization of 2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-4-(4-pyridinyl)-5-thiazolemethanol (JNJ-1930942), a novel positive allosteric modulator of the {alpha}7 nicotinic acetylcholine receptor. J. Pharmacol. Exp. Ther. 2011, 336:560-574.
16. Egea J., Rosa A.O., Sobrado M., Gandía L., López M.G., García A.G. Neuroprotection afforded by nicotine against oxygen and glucose deprivation in hippocampal slices is lost in alpha7 nicotinic receptor knockout mice. Neuroscience 2007, 145:866-872.
17. Faghih R., Gopalakrishnan M., Briggs C.A. Allosteric modulators of the alpha7 nicotinic acetylcholine receptor. J. Med. Chem. 2008, 51:701-712.
18. Ferchmin P.A., Perez D., Eterovic V.A., de Vellis J. Nicotinic receptors differentially regulate N-methyl-d-aspartate damage in acute hippocampal slices. J. Pharmacol. Exp. Ther. 2003, 305:1071-1078.
19. Floden A.M., Combs C.K. Beta-amyloid stimulates murine postnatal and adult microglia cultures in a unique manner. J. Neurosci. 2006, 26:4644-4648.
20. Freedman R., Olincy A., Buchanan R.W., Harris J.G., Gold J.M., Johnson L., Allensworth D., Guzman-Bonilla A., Clement B., Ball M.P., Kutnick J., Pender V., Martin L.F., Stevens K.E., Wagner B.D., Zerbe G.O., Soti F., Kem W.R. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am. J. Psychiatry 2008, 165:1040-1047.
21. Grønlien J.H., Håkerud M., Ween H., Thorin-Hagene K., Briggs C.A., Gopalakrishnan M., Malysz J. Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes. Mol. Pharmacol. 2007, 72:715-724.
22. Hosur V., Loring R.H. α4β2 nicotinic receptors partially mediate anti-inflammatory effects through Janus kinase 2-signal transducer and activator of transcription 3 but not calcium or cAMP signaling. Mol. Pharmacol. 2011, 79:167-174.
23. Hurst R.S., Hajós M., Raggenbass M., Wall T.M., Higdon N.R., Lawson J.A., Rutherford-Root K.L., Berkenpas M.B., Hoffmann W.E., Piotrowski D.W., Groppi V.E., Allaman G., Ogier R., Bertrand S., Bertrand D., Arneric S.P. A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J. Neurosci. 2005, 25:4396-4405.
24. Kaneko S., Maeda T., Kume T., Kochiyama H., Akaike A., Shimohama S., Kimura J. Nicotine protects cultured cortical neurons against glutamate-induced cytotoxicity via alpha7-neuronal receptors and neuronal CNS receptors. Brain Res. 1997, 765:135-140.
25. Kem W.R., Mahnir V.M., Prokai L., Papke R.L., Cao X., LeFrancois S., Wildeboer K., Prokai-Tatrai K., Porter-Papke J., Soti F. Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration. Mol. Pharmacol. 2004, 65:56-67.
26. Khan M.A.S., Farkhondeh M., Crombie J., Jacobson L., Kaneki M., Martyn J.A.J. Lipopolysaccharide up-regulates alpha7 acetylcholine receptors: stimulation with GTS-21 mitigates growth arrest of macrophages and improves survival in burned mice. Shock 2012, 38(2):213-219.
27. Kihara T., Shimohama S., Sawada H., Honda K., Nakamizo T., Shibasaki H., Kume T., Akaike A. Alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity. J. Biol. Chem. 2001, 276:13541-13546.
28. Kitagawa H., Takenouchi T., Azuma R., Wesnes K.A., Kramer W.G., Clody D.E., Burnett A.L. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology 2003, 28:542-551.
29. Kox M., van Velzen J.F., Pompe J.C., Hoedemaekers C.W., van der Hoeven J.G., Pickkers P. GTS-21 inhibits pro-inflammatory cytokine release independent of the Toll-like receptor stimulated via a transcriptional mechanism involving JAK2 activation. Biochem. Pharmacol. 2009, 78:863-872.
30. Kox M., Pompe J.C., Gordinou de Gouberville M.C., van der Hoeven J.G., Hoedemaekers C.W., Pickkers P. Effects of the α7 nicotinic acetylcholine receptor agonist GTS-21 on the innate immune response in humans. Shock 2011, 36:5-11.
31. Laudenbach V., Medja F., Zoli M., Rossi F.M., Evrard P., Changeux J.-P., Gressens P. Selective activation of central subtypes of the nicotinic acetylcholine receptor has opposite effects on neonatal excitotoxic brain injuries. FASEB J. 2002, 16:423-425.
32. Li D.-J., Tang Q., Shen F.-M., Su D.-F., Duan J.-L., Xi T. Overexpressed alpha7 nicotinic acetylcholine receptor inhibited proinflammatory cytokine release in NIH3T3 cells. J. Biosci. Bioeng. 2009, 108:85-91.
33. Meyer E.M., Tay E.T., Papke R.L., Meyers C., Huang G.L., de Fiebre C.M. 3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat alpha7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner. Brain Res. 1997, 768:49-56.
34. Miller B.A., Crum J.M., Tovar C.A., Ferguson A.R., Bresnahan J.C., Beattie M.S. Developmental stage of oligodendrocytes determines their response to activated microglia in vitro. J. Neuroinflammation 2007, 4:28.
35. Monji A., Kato T., Kanba S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin. Neurosci. 2009, 63:257-265.
36. Ng H.J., Whittemore E.R., Tran M.B., Hogenkamp D.J., Broide R.S., Johnstone T.B., Zheng L., Stevens K.E., Gee K.W. Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:8059-8064.
37. Nizri E., Irony-Tur-Sinai M., Lory O., Orr-Urtreger A., Lavi E., Brenner T. Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of Th1 and Th17 responses. J. Immunol. 2009, 183:6681-6688.
38. Olincy A., Harris J.G., Johnson L.L., Pender V., Kongs S., Allensworth D., Ellis J., Zerbe G.O., Leonard S., Stevens K.E., Stevens J.O., Martin L., Adler L.E., Soti F., Kem W.R., Freedman R. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch. Gen. Psychiatry 2006, 63:630-638.
39. Panaro M.A. Current opinions and perspectives on the role of immune system in the pathogenesis of Parkinsons disease. Curr. Pharm. 2012, 1-9.
40. Park H.J., Lee P.H., Ahn Y.W., Choi Y.J., Lee G., Lee D.-Y., Chung E.S., Jin B.K. Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action. Eur. J. Neurosci. 2007, 26:79-89.
41. Park J-sun, Woo M-sook, Kim D.-H., Kim D.-H., Hyun J-won, Kim W.-K., Lee J-chul, Kim H-sun Anti-inflammatory mechanisms of isoflavone metabolites in lipopolysaccharide-stimulated microglial cells. J. Pharmacol. Exp. Ther. 2007, 320:1237-1245.
42. Rosas-Ballina M., Goldstein R.S., Gallowitsch-Puerta M., Yang L., Valdés-Ferrer S.I., Patel N.B., Chavan S., Al-Abed Y., Yang H., Tracey K.J. The selective alpha7 agonist GTS-21 attenuates cytokine production in human whole blood and human monocytes activated by ligands for TLR2, TLR3, TLR4, TLR9, and RAGE. Mol. Med. 2009, 15:195-202.
43. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative CT method. Nat. Protoc. 2008, 3:1101-1108.
44. Shytle R.D., Mori T., Townsend K., Vendrame M., Sun N., Zeng J., Ehrhart J., Silver A.A., Sanberg P.R., Tan J. Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J. Neurochem. 2004, 89:337-343.
45. Suzuki T., Hide I., Matsubara A., Hama C., Harada K., Miyano K., Andrä M., Matsubayashi H., Sakai N., Kohsaka S., Inoue K., Nakata Y. Microglial alpha7 nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role. J. Neurosci. Res. 2006, 83:1461-1470.
46. Takeuchi H., Yanagida T., Inden M., Takata K., Kitamura Y., Yamakawa K., Sawada H., Izumi Y., Yamamoto N., Kihara T., Uemura K., Inoue H., Taniguchi T., Akaike A., Takahashi R., Shimohama S. Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models. J. Neurosci. Res. 2009, 87:576-585.
47. Thomsen M.S., Mikkelsen J.D. The α7 nicotinic acetylcholine receptor complex: one, two or multiple drug targets? Curr. Drug Targets 2012, 13(5):707-720.
48. Thomsen M.S., Hansen H.H., Timmermann D.B., Mikkelsen J.D. Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr. Pharm. Des. 2010, 16:323-343.
49. Timmermann D.B., Grønlien J.H., Kohlhaas K.L., Nielsen E.Ø., Dam E., Jørgensen T.D., Ahring P.K., Peters D., Holst D., Christensen J.K., Chrsitensen J.K., Malysz J., Briggs C.A., Gopalakrishnan M., Olsen G.M. An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J. Pharmacol. Exp. Ther. 2007, 323:294-307.
50. 2+. FASEB J. 2011, 25:2563-2573.
51. Tracey K.J. Physiology and immunology of the cholinergic antiinflammatory pathway. J. Clin. Invest. 2007, 117:289-296.
52. Tyagi E., Agrawal R., Nath C., Shukla R. Inhibitory role of cholinergic system mediated via alpha7 nicotinic acetylcholine receptor in LPS-induced neuro-inflammation. Innate Immun. 2010, 16:3-13.
53. Wang H., Yu M., Ochani M., Amella C.A., Tanovic M., Susarla S., Li J.H., Wang H., Yang H., Ulloa L., Al-Abed Y., Czura C.J., Tracey K.J. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003, 421:384-388.
54. Wessler I., Reinheimer T., Klapproth H., Schneider F.J., Racké K., Hammer R. Mammalian glial cells in culture synthesize acetylcholine. Naunyn Schmiedebergs Arch. Pharmacol. 1997, 356:694-697.
55. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat. Med. 2006, 12:1005-1015.